208 related articles for article (PubMed ID: 22500681)
1. Epidermal growth factor vaccine in non-small-cell lung cancer.
Gonzalez Marinello GM; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2012 Apr; 12(4):439-45. PubMed ID: 22500681
[TBL] [Abstract][Full Text] [Related]
2. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
Mellstedt H; Vansteenkiste J; Thatcher N
Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the immune system for the treatment of non-small-cell lung cancer.
Brahmer JR
J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
[TBL] [Abstract][Full Text] [Related]
6. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
7. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer.
Neninger E; Verdecia BG; Crombet T; Viada C; Pereda S; Leonard I; Mazorra Z; Fleites G; González M; Wilkinson B; González G; Lage A
J Immunother; 2009 Jan; 32(1):92-9. PubMed ID: 19307998
[TBL] [Abstract][Full Text] [Related]
8. Non-small-cell lung cancer vaccine therapy: a concise review.
O'Mahony D; Kummar S; Gutierrez ME
J Clin Oncol; 2005 Dec; 23(35):9022-8. PubMed ID: 16219932
[TBL] [Abstract][Full Text] [Related]
9. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination.
Van den Heuvel MM; Burgers SA; van Zandwijk N
Clin Lung Cancer; 2009 Mar; 10(2):99-105. PubMed ID: 19362952
[TBL] [Abstract][Full Text] [Related]
11. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
[TBL] [Abstract][Full Text] [Related]
12. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
Sangha R; Butts C
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
[TBL] [Abstract][Full Text] [Related]
13. Emepepimut-S for non-small cell lung cancer.
Corrales-Rodriguez L; Blais N; Soulières D
Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
[TBL] [Abstract][Full Text] [Related]
14. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.
Raez LE; Santos ES; Mudad R; Podack ER
Expert Rev Anticancer Ther; 2005 Aug; 5(4):635-44. PubMed ID: 16111464
[TBL] [Abstract][Full Text] [Related]
16. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant immunotherapy for non-small cell lung cancer.
Tucker ZC; Laguna BA; Moon E; Singhal S
Cancer Treat Rev; 2012 Oct; 38(6):650-61. PubMed ID: 22226940
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
[TBL] [Abstract][Full Text] [Related]
19. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
Rossi A
Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
[No Abstract] [Full Text] [Related]
20. Novel targeted agents for lung cancer.
West HJ
Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]